Evidence map›Paper›PMID 37428862›Full record

ArticleBlood advances2023

Natural history and variability in albuminuria in pediatric and murine sickle cell anemia.

Malgorzata Kasztan, Inmaculada Aban, Kayla Baker, Michael Ho, Chibuzo Ilonze, Jeffrey Lebensburger

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Impact of renal iron overload on sickle cell nephropathy in a humanized mouse model.American journal of physiology. Renal physiology · 2026
    Article
  2. Review
  3. Observational
  4. Review
  5. Observational
  6. Article
  7. Article
  8. Sickle Cell Disease and CKD: An Update.American journal of nephrology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Malgorzata KasztanDivision of Pediatric Hematology Oncology, The University of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0003-3345-1580
Inmaculada AbanDepartment of Biostatistics, The University of Alabama at Birmingham, Birmingham, AL.
Kayla BakerHeersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL.
Michael HoHeersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL.ORCID 0009-0004-9535-2064
Chibuzo IlonzeDivision of Pediatric Hematology Oncology, The University of Alabama at Birmingham, Birmingham, AL.
Jeffrey LebensburgerDivision of Pediatric Hematology Oncology, The University of Alabama at Birmingham, Birmingham, AL.
University of Alabama at Birmingham · USUniversity of Alabama · US

Funding

Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell AnemiaR01HL153386 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LEBENSBURGER, JEFFREY D · 2020 to 2023
$3.8M
The Role of Endothelin-1 in Tubular Injury in Sickle Cell DiseaseR00HL144817 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KASZTAN, MALGORZATA · 2021 to 2023
$747k
PRedOctoral PhD and MD research training in TEams (PROmoTE)R25DK112731 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Orlando M Gutierrez, Jennifer S Pollock · 2019 to 2026
$741k
NHLBI NIH HHS R00 HL144817NHLBI NIH HHS R01 HL153386NIDDK NIH HHS R25 DK112731
6 · The paper itself

Abstract

It is critical to characterize the natural history of albuminuria in patients with sickle cell anemia (SCA); however, these data are currently lacking and affecting evidence-based guidelines. We performed a natural history study of the development of pediatric albuminuria. We identified participants with hemoglobin SS/SB0 thalassemia ≥5 years with albumin to creatinine ratio (ACR) measurements performed at a steady-state clinic visit. Participants were characterized as either persistent, intermittent, or never albuminuria. We determined the prevalence of persistent albuminuria, use of ACR ≥100 mg/g as a predictor, and variation in ACR measurements. We mirrored this study to determine the variation in albuminuria measurements in the SCA murine model. Among 355 participants with HbSS/SB0 thalassemia with 1728 ACR measurements, we identified 17% with persistent and 13% with intermittent albuminuria. Thirteen percent of participants with persistent albuminuria developed an abnormal ACR before 10 years of age. A single ACR measurement ≥100 mg/g was associated with 55.5 times (95% confidence interval, 12.3-527) higher odds of having persistent albuminuria. Among participants with ACR ≥100 mg/g, we identified significant variability in the results of repeated measurements. The median ACR at the initial and next measurements were 175.8 mg/g (interquartile range [IQR], 135-242) and 117.3 mg/g (IQR, 64-292). The human variability in ACR was mirrored by ∼20% variability in albuminuria in murine model. This evidence suggests adopting standards for repeating ACR measurements, consider screening for ACR before 10 years of age, and using an ACR >100 mg/g as a risk factor for progression. Pediatric and murine renoprotective clinical trials need to consider the high variability in repeated ACR measurements.

Indexed as

Anemia, Sickle CellThalassemiaAlbuminuriaAnimalsChildCreatinineDisease Models, AnimalGlomerular Filtration RateHemoglobin, SickleHumansMiceCreatinineHemoglobin, Sickle

Identifiers

PMID37428862
PMCPMC10685147
OpenAlexW4383754892

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.